L-651,392, a potent leukotriene inhibitor, controls inflammatory process in Escherichia coli pyelonephritis.
In this study, the relationship between leukotrienes, peritubular cell infiltration with polymorphonuclear cells (PMNs) and renal tubular damage was investigated in a rat model of acute ascending pyelonephritis. Infection was induced by the injection of 10(5) CFU of Escherichia coli into the bladder and occlusion of the left ureter for 24 h. Treatment of infected animals was started 24 h after the induction of pyelonephritis with either hydrocortisone (25 mg/kg of body weight per day), the leukotriene inhibitor L-651,392 (10 mg/kg/day), or the vehicle of L-651,392 and was maintained for 5 days. At the end of treatment, the animals were killed, serum was collected, and both kidneys were removed for colony counts and histopathology. Renal function was evaluated by the measurement of blood urea nitrogen levels and creatinine clearance. The numbers of PMNs and mononuclear cells (MNs) in the cortex and medulla were recorded for all groups on plastic sections done from the left kidney. Infection alone (vehicle of L-651,392) resulted in intensive interstitial infiltration and a severe tubular destruction in the cortex. Treatment with hydrocortisone did not prevent PMN migration and tissue damage. By contrast, treatment with L-651,392 resulted in a significant reduction in PMNs (P < 0.001 in comparisons with all other groups) and greater preservation of the tubular structure despite identical bacterial counts than in the group receiving hydrocortisone. We conclude that L-651,392 prevents inflammatory cells from reaching the site of infection and protects the kidney from tubular damage associated with inflammation during pyelonephritis. Inhibitors of leukotrienes should be further investigated for their potential benefit as adjuvants to antibiotherapy in the treatment of pyelonephritis.
Tardif
M
M
Laboratoire et Service d'Infectiologie, Centre de Recherche du Centre Hospitalier de l'Université Laval, Ste-Foy, Québec, Canada.
Beauchamp
D
D
Bergeron
Y
Y
Lessard
C
C
Gourde
P
P
Bergeron
M G
MG
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D005260:Female; D006854:Hydrocortisone / Q000627:therapeutic use; D007672:Kidney Cortex / Q000382:microbiology / Q000473:pathology; D007677:Kidney Function Tests; D007679:Kidney Medulla / Q000382:microbiology / Q000473:pathology; D007684:Kidney Tubules / Q000382:microbiology / Q000473:pathology; D020024:Leukotriene Antagonists; D016859:Lipoxygenase Inhibitors / Q000627:therapeutic use*; D008854:Microscopy, Electron; D009504:Neutrophils / Q000187:drug effects; D010640:Phenothiazines / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley
D000894:Anti-Inflammatory Agents, Non-Steroidal; D020024:Leukotriene Antagonists; D016859:Lipoxygenase Inhibitors; D010640:Phenothiazines; C053726:4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one; D006854:Hydrocortisone